Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies.

Inclusion Criteria:

• Have a history of heterozygous familial hypercholesterolemia (HeFH) by 1) Genotyping (not a screening assessment), WHO Criteria/Dutch Lipid Clinical Network Criteriawith a score of > 8 points; and/or Simon Broome Register Diagnostic Criteria fordefinite or possible Familial Hypercholesterolemia (FH)

• Maximally tolerated lipid Modifying therapy for at least 8 weeks prior to screeningsuch as: ATV (40 or 80), or (ROS 20 or 40 mg), Ezetimide, Bempedoic Acid, PCSK9targeted therapy for at least 4 doses

• Fasting serum LDL-C ≥70 mg/dL (≥1.80 mmol/L)

Exclusion Criteria:

• New York Heart Association class II or IV heart failure or last known leftventricular ejection fraction < 30%;

• Hospitalized for heart failure within 5 years prior to Screening

• Major adverse cardiac event (MACE) within 3 months prior to Screening;

• HbA1c ≥10%, or fasting glucose

• Formal diagnosis of homozygous familial hypercholesterolemia (HoFH)

• Uncontrolled severe hypertension, defined as either systolic blood pressure ≥ 160mmHg or diastolic blood pressure ≥100 mmHg prior to Randomization